This site is intended for healthcare professionals

Phase III Beovu data in KESTREL and KITE studies show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept.- Novartis.

Read time: 2 mins
Last updated:2nd May 2021
Published:2nd May 2021
Condition: Diabetic Macular Oedema
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest